Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted

被引:69
|
作者
Yamanaka, H [1 ]
Nakajima, M [1 ]
Nishimura, K [1 ]
Yoshida, R [1 ]
Fukami, T [1 ]
Katoh, M [1 ]
Yokoi, T [1 ]
机构
[1] Kanazawa Univ, Grad Sch Med Sci, Div Pharmaceut Sci, Kanazawa, Ishikawa 9201192, Japan
关键词
nicotine; LC-MS/MS; CYP2A6; poor metabolizer;
D O I
10.1016/j.ejps.2004.04.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Generally, 70-80% of absorbed nicotine is mainly metabolized to cotinine by cytochrome P450 (CYP) 2A6. There is genetic polymorphism in the human CYP2A6 gene. Among several mutated alleles, CYP2A6*4 allele is a whole deleted type. The purpose of the present study was to clarify the metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. We developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for nicotine and its nine metabolites. Excretion levels of nicotine and its metabolites in 24 h accumulated urine after the chewing of one piece of nicotine gum were evaluated in five Japanese subjects whose CYP2A6 genotype was determined. In three subjects with CYP2A6*1A/CYP2A6*1A, CYP2A6*1A/CYP2A6*1B, and CYP2A6*1A/CYP2A6*4 (group I), nicotine was mainly excreted as cotinine, trans-3'-hydroxycotinine, and their glucuronide (approximately 60%). In contrast, in two subjects with CYP2A6*4/CYP2A6*4 (group II), trace levels of cotinine, cotinine N-glucuronide, and cotinine 1'-N-oxide were detected. Trans-3'-hydroxycotinine and its O-glucuronide were not detected. The excretion levels of nicotine itself, nicotine N-glucuronide, and nicotine 1'-N-oxide were higher than those in the other three subjects. The total excretion levels of these three compounds were approximately 95% in group II versus 35% in group I. However, the sum of the excretion levels of nicotine and all metabolites was similar among these five subjects. This is the first report of the metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:419 / 425
页数:7
相关论文
共 50 条
  • [31] Transcriptional regulation of the human CYP2A6 gene
    Pitarque, M
    Rodríguez-Antona, C
    Oscarson, M
    Ingelman-Sundberg, M
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (02): : 814 - 822
  • [32] Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans
    Nakajima, M
    Yamagishi, S
    Yamamoto, H
    Yamamoto, T
    Kuroiwa, Y
    Yokoi, T
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (01) : 57 - 69
  • [33] Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity
    Oscarson, M
    McLellan, RA
    Asp, V
    Ledesma, M
    Ruiz, MLB
    Sinues, B
    Rautio, A
    Ingelman-Sundberg, M
    HUMAN MUTATION, 2002, 20 (04) : 275 - 283
  • [34] Functional Characterization of Cytochrome P450 2A6 Allelic Variants CYP2A6*15, CYP2A6*16, CYP2A6*21, and CYP2A6*22
    Tiong, Kai Hung
    Yiap, Beow Chin
    Tan, Eng Lai
    Ismail, Rusli
    Ong, Chin Eng
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (05) : 745 - 751
  • [35] Effects of chronic nicotine treatment on CYP2A6, CYP2B6, and nicotine/cotinine metabolism in African Green monkeys
    Schoedel, KA
    Miksys, S
    Nolte, H
    Sellers, EM
    Nwaneshiudu, A
    Tyndale, RF
    FASEB JOURNAL, 2001, 15 (04): : A573 - A573
  • [36] Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method
    Mwenifumbo, JC
    Myers, MG
    Wall, TL
    Lin, SK
    Sellers, EM
    Tyndale, RF
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (03): : 189 - 192
  • [37] Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity
    Fukami, T
    Nakajima, M
    Higashi, E
    Yamanaka, H
    Sakai, H
    McLeod, HL
    Yokoi, T
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (08) : 1202 - 1210
  • [38] The significance of the homozygous CYP2A6 deletion on nicotine metabolism:: A new genotyping method of CYP2A6 using a single PCR-RFLP
    Kitagawa, K
    Kunugita, N
    Katoh, T
    Yang, MH
    Kawamoto, T
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 262 (01) : 146 - 151
  • [39] Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme -: an in silico approach
    Rahnasto, M.
    Wittekindt, C.
    Juvonen, R. O.
    Turpeinen, M.
    Petsalo, A.
    Pelkonen, O.
    Poso, A.
    Stahl, G.
    Holtje, H-D
    Raunio, H.
    PHARMACOGENOMICS JOURNAL, 2008, 8 (05): : 328 - 338
  • [40] Nicotine metabolite ratio as a predictor of CYP2A6 phenotypic activity.
    Dempsey, DA
    Tutka, P
    Jacob, P
    Benowitz, NL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P24 - P24